{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:26:46Z","timestamp":1790008006831,"version":"4.0.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor cell burden in dogs with lymphoma cannot be assessed accurately by diagnostic evaluation during clinical complete remission (CR). Recent advances in polymerase chain reaction (PCR)-based methods enabled us to quantify minimal residual disease (MRD) in canine lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To quantify MRD in dogs with lymphoma treated with multidrug chemotherapy and to correlate it with remission duration after chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Seventeen dogs with lymphoma that achieved CR by multidrug chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Rearranged immunoglobulin heavy chain or T-cell receptor \u03b3 chain gene fragments from lymphoma cells were PCR amplified and sequenced to prepare clone-specific primers and probes for real-time PCR to quantify MRD. MRD in the peripheral blood was monitored during and at the end of a 25-week multidrug chemotherapy protocol. Correlation between MRD at the end of chemotherapy and remission duration after chemotherapy was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MRD gradually decreased after initiation of multidrug chemotherapy, reached a nadir as low as &amp;lt;0.019\u20131.0\u2003cells\/\u03bcL at weeks 4\u201317, and remained low or slightly increased until week 25. MRD at the end of chemotherapy was negatively correlated with remission duration from the end of chemotherapy to relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Clinical Importance<\/jats:title>\n                    <jats:p>MRD could be an objective marker to indicate tumor cell burden in dogs with lymphoma even in clinical CR. MRD at the end of chemotherapy could be a prognostic factor to predict remission duration after chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2010.0536.x","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T15:01:08Z","timestamp":1274194868000},"page":"897-903","source":"Crossref","is-referenced-by-count":26,"title":["Monitoring of Minimal Residual Disease (MRD) after Multidrug Chemotherapy and Its Correlation to Outcome in Dogs with Lymphoma: A Proof-of-Concept Pilot Study"],"prefix":"10.1093","volume":"24","author":[{"given":"J.","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Graduate School of Agricultural and Life Sciences, The University of Tokyo Department of Veterinary Internal Medicine, , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Graduate School of Agricultural and Life Sciences, The University of Tokyo Department of Veterinary Internal Medicine, , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Setoguchi","sequence":"additional","affiliation":[{"name":"Graduate School of Agricultural and Life Sciences, The University of Tokyo Department of Veterinary Internal Medicine, , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Fujino","sequence":"additional","affiliation":[{"name":"Graduate School of Agricultural and Life Sciences, The University of Tokyo Department of Veterinary Internal Medicine, , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ohno","sequence":"additional","affiliation":[{"name":"Graduate School of Agricultural and Life Sciences, The University of Tokyo Department of Veterinary Internal Medicine, , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Graduate School of Agricultural and Life Sciences, The University of Tokyo Department of Veterinary Internal Medicine, , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,7,1]]},"reference":[{"key":"2026020303160190600_b1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.2460\/javma.1981.178.11.1178","article-title":"Cyclic combination chemotherapy of canine lymphosarcoma","volume":"178","author":"MacEwen","year":"1981","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303160190600_b2","first-page":"159","article-title":"Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone","volume":"19","author":"Cotter","year":"1983","journal-title":"I. Treatment of dogs"},{"key":"2026020303160190600_b3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1939-1676.1993.tb01021.x","article-title":"Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma","volume":"7","author":"Keller","year":"1993","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1939-1676.1997.tb00476.x","article-title":"Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma","volume":"11","author":"Myers","year":"1997","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1939-1676.1998.tb02151.x","article-title":"A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma","volume":"12","author":"Zemann","year":"1998","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b6","first-page":"704","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b7","first-page":"52","article-title":"Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma","volume":"47","author":"Siedlecki","year":"2006","journal-title":"Can Vet J"},{"key":"2026020303160190600_b8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1939-1676.2007.tb01960.x","article-title":"Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma","volume":"21","author":"Rassnick","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b9","first-page":"1355","article-title":"Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma","volume":"21","author":"Hosoya","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2460\/javma.232.6.879","article-title":"Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma","volume":"232","author":"Simon","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303160190600_b11","first-page":"355","article-title":"A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma","volume":"20","author":"Frimberger","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"2026020303160190600_b13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"2026020303160190600_b14","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"2026020303160190600_b15","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.V82.6.1689.1689","article-title":"Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML\/RAR-alpha fusion mRNA","volume":"82","author":"Miller","year":"1993","journal-title":"Blood"},{"key":"2026020303160190600_b16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.vetimm.2008.09.004","article-title":"Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction","volume":"126","author":"Yamazaki","year":"2008","journal-title":"Vet Immunol Immunopathol"},{"key":"2026020303160190600_b17","first-page":"35","article-title":"Cytohistological and immunological classification of canine malignant lymphomas","volume":"117","author":"Fournel-Fleury","year":"1997","journal-title":"Comparison with human non-Hodgkin's lymphomas"},{"key":"2026020303160190600_b18","first-page":"46","article-title":"TNM Classification of Tumours in Domestic Animals","author":"Owen","year":"1980"},{"key":"2026020303160190600_b19","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1939-1676.2006.tb00719.x","article-title":"Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma","volume":"20","author":"Alvarez","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1354\/vp.40-1-32","article-title":"Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes","volume":"40","author":"Burnett","year":"2003","journal-title":"Vet Pathol"},{"key":"2026020303160190600_b21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.vetimm.2005.10.009","article-title":"Development of the polymerase chain reaction assay based on the canine genome database for detection of monoclonality in B cell lymphoma","volume":"110","author":"Tamura","year":"2006","journal-title":"Vet Immunol Immunopathol"},{"key":"2026020303160190600_b22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1354\/vp.43-3-241","article-title":"Canine indolent nodular lymphoma","volume":"43","author":"Valli","year":"2006","journal-title":"Vet Pathol"},{"key":"2026020303160190600_b23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1939-1676.2006.tb02864.x","article-title":"Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma","volume":"20","author":"Lana","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303160190600_b24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(94)90988-1","article-title":"Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction","volume":"343","author":"Brisco","year":"1994","journal-title":"Lancet"},{"key":"2026020303160190600_b25","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood.V87.12.5251.bloodjournal87125251","article-title":"Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia","volume":"87","author":"Brisco","year":"1996","journal-title":"Blood"},{"key":"2026020303160190600_b26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1939-165X.2004.tb00357.x","article-title":"Morphologic, immunohistochemical, and molecular characterization of hepatosplenic T-cell lymphoma in a dog","volume":"33","author":"Cienava","year":"2004","journal-title":"Vet Clin Pathol"},{"key":"2026020303160190600_b27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1354\/vp.40-5-556","article-title":"Hepatosplenic lymphoma in a dog","volume":"40","author":"Fry","year":"2003","journal-title":"Vet Pathol"},{"key":"2026020303160190600_b28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/01652176.1996.9694630","article-title":"Diagnostic value and reproducibility of fine-needle aspiration cytology in canine malignant lymphoma","volume":"18","author":"Teske","year":"1996","journal-title":"Vet Q"},{"key":"2026020303160190600_b29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tvjl.2003.10.009","article-title":"Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy","volume":"167","author":"Ponce","year":"2004","journal-title":"Vet J"},{"key":"2026020303160190600_b30","first-page":"732","article-title":"Textbook of Veterinary Internal Medicine","author":"Vail","year":"2005","edition":"6th ed"},{"key":"2026020303160190600_b31","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2460\/javma.1994.205.12.1722","article-title":"Prognostic factors for treatment of malignant lymphoma in dogs","volume":"205","author":"Teske","year":"1994","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303160190600_b32","first-page":"1691","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma","volume":"15","author":"Brugger","year":"2004","journal-title":"A prospective, multicenter phase II study"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2010.0536.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/4\/897\/66654221\/j.1939-1676.2010.0536.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/4\/897\/66654221\/j.1939-1676.2010.0536.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:16:12Z","timestamp":1770106572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/24\/4\/897\/8447248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2010.0536.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,7]]},"published":{"date-parts":[[2010,7,1]]}}}